Bupivacaine/Meloxicam Prolonged Release: A Review in Postoperative Pain.
Hannah A Blair
https://pubmed.ncbi.nlm.nih.gov/34228280/Actively Recruiting
Led by Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · Updated on 2026-10-28
150
Participants Needed
1
Research Sites
4 weeks
Total Duration
This research evaluates pain relief and opioid use after Robot Assisted Total Knee Arthroplasty RATKA by comparing a newer extended-release injection called Zynrelef to standard periarticular injections. The study aims to see if Zynrelef reduces pain and opioid consumption better than traditional treatments. It also looks at patients use of other over-the-counter pain medications after surgery. Participants receive one of two periarticular injections during their RATKA surgery either the extended-release bupivacaine-meloxicam Zynrelef or the standard combination of bupivacaine, ketorolac, and lidocaine. This randomized, double-blind study follows patients receiving standard care at Allegheny Health Network facilities. Data collection involves patient surveys and medical record reviews. Participants report their pain levels using the Numeric Rating Scale daily for three days after surgery and record opioid and other pain medication use during this period. Paper surveys are collected at the next postoperative visit, and researchers review electronic medical records for demographics and outcomes. The primary measures focus on opioid use and pain scores within the first three days post-operation, with safety monitored during this time as well.
CONDITIONS
Post-Operative Pain Relief: Zynrelef or Periarticular Injections in RATKA
O
Obinna Ajah, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Zynrelef (extended-release) | Standard Periarticular Injection |
|---|---|---|
| What is it? | Zynrelef is an extended-release periarticular injection combining bupivacaine (a local anesthetic) and meloxicam (an anti-inflammatory), given at the time of knee replacement to provide sustained pain relief after surgery. | The control is a standard periarticular injection composed of bupivacaine (a local anesthetic), ketorolac (an anti-inflammatory), and lidocaine, administered during knee replacement for post-operative pain management. |
| Role in this study | This intervention is being evaluated for its ability to reduce pain and opioid use after knee replacement compared to standard periarticular injection. | This regimen is the standard periarticular analgesic given at surgery and serves as the comparator arm in the randomized trial. |
| Main clinical use | Intended for perioperative pain control and to limit opioid requirements after total knee replacement in adults with knee osteoarthritis. | Used as a multi-agent periarticular analgesic for pain management after knee replacement surgery. |
| How is it given or performed? | Single periarticular injection administered by the surgeon at the time of knee replacement surgery; Zynrelef delivers extended-release medication directly to tissue around the joint. | Single periarticular injection given at the time of surgery, containing bupivacaine, ketorolac, and lidocaine as local anesthesia and anti-inflammatory agents. |
| Maturity of evidence | Multiple clinical trials—including randomized studies—evaluate extended-release bupivacaine-meloxicam for controlling pain and reducing opioid consumption after knee replacement; most studies show non-inferiority to standard periarticular injection. | Standard periarticular injection with multi-agent combinations is supported by guideline recommendations and decades of use for knee replacement pain management; its effectiveness is well established. |
| Important risks, side effects, or safety considerations | The main risks are local anesthetic toxicity, bleeding, and possible allergic reaction. Extended-release bupivacaine-meloxicam has a safety profile similar to standard formulations, with rare instances of wound complications or delayed healing reported. | Risks include local anesthetic systemic toxicity, bleeding, allergy, and, rarely, wound complications. The established risk profile is well known from decades of use; no major new risks have emerged. |
| Important limitations | Extended-release bupivacaine-meloxicam is more expensive than standard injection, and some studies show it does not further reduce pain or opioid use compared to established regimens. Long-term comparative safety and cost-effectiveness data remain limited. | Standard periarticular injections' effectiveness can vary depending on the surgeon’s injection technique and patient factors. There is also variability in mixture components across institutions. Shorter duration of pain relief may necessitate additional analgesic medication. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Day of surgery
Participants receive either the extended-release bupivacaine-meloxicam injection (Zynrelef) or the standard periarticular injection during their Robot Assisted Total Knee Arthroplasty surgery.
1 surgical visit
Duration - 3 days
Participants report their pain daily using the Numeric Rating Scale and record opioid and other pain medication use for 3 days after surgery. Paper surveys are collected at the next postoperative visit, and medical records are reviewed.
Daily pain reporting for 3 days and 1 postoperative visit
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Hannah A Blair
https://pubmed.ncbi.nlm.nih.gov/34228280/Aiyong Cui, Huizi Li, Dawei Wang...
https://pubmed.ncbi.nlm.nih.gov/34505846/Harold I Salmons, Adam W Amundson, Christopher M Duncan...
https://pubmed.ncbi.nlm.nih.gov/40711999/Peter Y Joo, Antonia F Chen, Jarod Richards...
https://pubmed.ncbi.nlm.nih.gov/35848995/Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Lead Sponsor